Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Stomach Cancer Sector?

In the past few years, the market size for stomach cancer has seen significant expansion. It will surge from a value of $3.27 billion in 2024 to $3.74 billion in 2025, representing an annual compounded growth rate (CAGR) of 14.1%. Factors driving growth during this historic period include a rising incidence of Helicobacter pylori infection, advancements in the development of targeted therapies, more frequent use of combination chemotherapy regimens, greater accessibility of immunotherapy treatments, and changes in lifestyle.

In the coming years, the market size for stomach cancer is predicted to witness significant growth, reaching $6.28 billion in 2029 with a CAGR of 13.9%. This predicted growth for the period under forecast can be credited to factors like an uptick in worldwide incidences of stomach cancer, enhanced expenditure on healthcare from public and private entities, more approvals for targeted therapies and biologics, heightened interest in oncology from pharmaceutical companies, and increased partnerships between research institutions and biotech companies. The forecast period will see key trends like the inclusion of companion diagnostics, the integration of genomic testing in routine clinical practices, advancements in immunotherapy combinations, innovations in endoscopic methodologies, and progress in the field of microbiome-based treatments.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

What Forces Are Driving The Growth Of The Stomach Cancer Market?

The increasing incidence of Helicobacter pylori infection is anticipated to boost the expansion of the stomach cancer market. This infection is a condition triggered by the Helicobacter pylori bacteria, that resides in the stomach’s lining, possibly leading to inflammation, ulcers, and a higher probability of stomach cancer. The primary reasons for the surge in Helicobacter pylori infections are substandard sanitation practices, enabling the spread of the bacteria via fecal-oral and oral-oral routes in crowded or unsanitary living conditions. The infection contributes to stomach cancer by causing ongoing inflammation and cellular damage in the stomach lining, resulting in precancerous alterations and tumor growth. For example, the Canadian government reported in November 2024 that the reinfection rate of Helicobacter pylori was 19% in 2023, with the rate differing based on parameters like geographical location and age category. Hence, the escalating incidence of Helicobacter pylori infection is fueling the expansion of the stomach cancer market.

How Is The Stomach Cancer Industry Segmented Across Key Parameters?

The stomach cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Adenocarcinoma: Intestinal Type, Diffuse Type

2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma

3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors

4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid

5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

What Long-Term Trends Are Likely To Affect The Stomach Cancer Market?

Leading enterprises in the stomach cancer treatment market are innovating by creating advanced solutions like claudin (CLDN18.2)-targeted cytolytic antibody therapy. This move aims to increase precision in primary treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. The claudin (CLDN18.2)-targeted cytolytic antibody therapy makes use of a unique antibody that selectively binds to CLDN18.2-expressing tumorous cells, inducing cytotoxic effects when integrated with chemotherapy, thereby enhancing both the progression-free and overall survival rates. For example, Astellas Pharma US, Inc., a pharmaceutical corporation based in Japan, introduced Vyloy (zolbetuximab-clzb) in October 2024. This is a claudin (CLDN18.2)-directed cytolytic antibody deployed in the treatment of gastric and gastroesophageal junction (GEJ) cancer. Administered intravenously alongside fluoropyrimidine- and platinum-based chemotherapy, this innovative biologic therapy provided a median progression-free survival benefit of up to 10.6 months and overall survival of up to 18.2 months during clinical tests. This therapy precisely targets CLDN18.2-positive cancer cells, reduces toxicity outside the target and heightens treatment specificity, thus making a substantial breakthrough in the field of personalised oncology for advanced gastric cancer.

Which Companies Currently Dominate The Competitive Landscape In The Stomach Cancer Industry?

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis Ag, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Eli Lilly And Company, Amgen Inc, Mayo Clinic, Daiichi Sankyo Company Limited., Illumina Inc., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited., Guardant Health Inc., Zai Lab Limited., MacroGenics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Which Geographic Regions Are Driving Demand In The Stomach Cancer Market?

North America was the largest region in the stomach cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25913&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model